News

Note: This story was updated Feb. 9, 2021, to clarify details surrounding the grant Chronic Care Collaborative received from Adira.  Greg Smiley’s world changed abruptly in 2013. He was racing down a mountain road on an outback cycling trip in South Africa, when he hit an obstruction in the road…

Coya Therapeutics has raised $10 million in funding to advance the development of ALS001, a potential regulatory T-cell (Treg) therapy aiming to halt amyotrophic lateral sclerosis (ALS) progression, now in a Phase 2 study in patients. Proceeds raised in this series A funding round will also be used to…

A new project run by a consortium of European institutions aims to improve the care of people with amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS) through targeted use of artificial intelligence (AI). Called BRAINTEASER, the four-year study will monitor some 300 participants using various wearable sensors and…

While progress was made last year on newborn screening and other policy issues critical to rare disease patients, a “State Report Card” argues that many concerns — notably out-of-pocket costs for prescription medicines and access to affordable comprehensive care — still need attention. Those were the findings of the…

An imaging technique, called 31-phosphorus magnetic resonance spectroscopy (MRS), can be used to assess mitochondrial abnormalities in people with amyotrophic lateral sclerosis (ALS), a new study demonstrates. This non-invasive procedure could be useful for evaluating potential ALS treatments, researchers suggested. The study, “Magnetic resonance spectroscopy…

As a new U.S. Congress prepares to start the annual process of determining funding for federal programs, the ALS Association is asking its advocacy network to press their legislators to expand support for research in amyotrophic lateral sclerosis (ALS). “This year, the ALS Association will aggressively pursue new and…

Abnormalities in the activity of the protein TDP-43, whose gene is often mutated in amyotrophic lateral sclerosis (ALS), can increase DNA damage in cells, a study shows. These findings shed light on the molecular underpinnings of ALS, and may open new avenues for treatment, its researchers said. The study,…

People with amyotrophic lateral sclerosis (ALS) who use melatonin have better survival outcomes and experience slower disease progression, a new analysis indicates. The findings suggest that melatonin may be beneficial for people with ALS. However, because the analysis was not designed to find cause-and-effect relationships, further studies are needed,…

Work into moving M102, an investigative treatment for amyotrophic lateral sclerosis (ALS), into testing in people has been given a boost by a £1.6 million research grant awarded to Aclipse Therapeutics and the…

A patent application allowing MediciNova to use its investigational therapy ibudilast (MN-166) in combination with riluzole to treat people with amyotrophic lateral sclerosis (ALS) has been approved for issue in Japan. The patent request filed with the Japan Patent Office covers a wide range of oral doses and dosing…